

Sheet 1 of 1

FORM PTO 1449 (modified)		Attorney Docket - P71167US0
U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		National Stage of - PCT/EP2004/010604
LIST OF REFERENCES CITED BY APPLICANT(S) (Use several sheets if necessary)		Applicant - Sheriff et al.
		Filing Date - March 22, 2006

## U.S. PATENT DOCUMENTS

Examiner <sup>†</sup>	Ref. #	Document No.		Date	Patentee/Applicant

## FOREIGN PATENT DOCUMENTS

	Country	Document No.	Translation <input checked="" type="checkbox"/>	Abstract <input type="checkbox"/>	Date	Patentee
/S.W./	WO	02/08189 A	<input checked="" type="checkbox"/>	<input type="checkbox"/>	01-31-2002	REID et al.
/S.W./	WO	98/53846	<input checked="" type="checkbox"/>	<input type="checkbox"/>	12-03-1998	PILON et al.
/S.W./	WO	98/55504	<input checked="" type="checkbox"/>	<input type="checkbox"/>	12-10-1998	MOUNIER et al.
/S.W./	WO	9620959	<input type="checkbox"/>	<input checked="" type="checkbox"/>	07-11-1996	KAWAUCHI et al.
			<input type="checkbox"/>	<input type="checkbox"/>		
			<input type="checkbox"/>	<input type="checkbox"/>		

## NON-PATENT DOCUMENTS

Examiner <sup>†</sup>	Ref. #	Author (In CAPITAL LETTERS), Title, Book or Periodical, Volume, Date, Pages
/S.W./		K. Hansford et al.: "D-tyrosine as a Chiral Precursor to Potent Inhibitors of Human Nonpancreatic Secretory Phospholipase A <sub>2</sub> (IIa) with Antinflammatory Activity." CHEMBIOCHEM, vol. 4, no. 2-3, 3 March 2003, pgs. 181-185
/S.W./		M. Menschikowski et al.: "Expression of Secretory group IIa phospholipase A <sub>2</sub> in Relation to the Presence of Microbial Agents, Macrophage Infiltrates, and Transcripts of Proinflammatory Cytokines in Human Aortic Tissues."
/S.W./		D. Fenard et al.: "Secreted phospholipase A <sub>2</sub> , a new class HIV Inhibitors that block virus entry into host cells." THE JOURNAL OF CLINICAL INVESTIGATION, vol. 104, no. 5, September 1999, pgs. 611-618

Examiner Signature	/Sharon Wen/	Date Considered
		10/23/2007

<sup>†</sup>Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

MAY 02 2006



Sheet 1 of 1

FORM PTO 1449 (modified)

U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICE  
LIST OF REFERENCES CITED BY APPLICANT(S)  
(Use several sheets if necessary)

Attorney Docket - P71167US0

Application No. - 10/572,875

Applicant - Sheriff et al.

Filing Date - March 22, 2006

## U.S. PATENT DOCUMENTS

Examiner <sup>1</sup>	Ref. #	Document No.		Date	Patentee/Applicant

## FOREIGN PATENT DOCUMENTS

	Country	Document No.	Translation Abstract	Date	Patentee
			<input type="checkbox"/> <input type="checkbox"/>		
			<input type="checkbox"/> <input type="checkbox"/>		
			<input type="checkbox"/> <input type="checkbox"/>		

## NON-PATENT DOCUMENTS

Examiner <sup>1</sup>	Ref. #	Author (In CAPITAL LETTERS), Title, Book or Periodical, Volume, Date, Pages
/S.W./		Hundley, T.R. et al., "Characteristics of Arachidonic Acid Generation in Human Basophils: Relationship Between the Effects of Inhibitors of Secretory Phospholipase A <sub>2</sub> Activity and Leukotriene C <sub>4</sub> Release," The Journal of Pharmacology and Experimental Therapeutics, Mar 1998, Vol. 284, No. 3, pgs. 847-857
/S.W./		Thwin, Muang-Muang et al., "Functional site of endogenous phospholipase A <sub>2</sub> inhibitor from python serum," European Journal of Biochemistry/Febs. Jan 2002, vol. 269, 719-727
/S.W./		Furue, Shingo, MS. et al., "Therapeutic time-window of a group IIA phospholipase A <sub>2</sub> inhibitor in rabbit acute lung injury: Correlation with lung surfactant protection," Critical Care Medicine, April 2001, vol. 29, no. 4, pgs. 719-727
/S.W./		Niessen, Hans W.M. et al., "Type II secretory phospholipase A2 in cardiovascular disease: a mediator in atherosclerosis and ischemic damage to cardiomyocytes?" Cardiovascular Research, 15 Oct. 2003, vol. 60, no. 1, 4 September 2003, pgs. 68-77
/S.W./		Graff, Jeremy R. et al., "Expression of Group IIA Secretory Phospholipase A2 Increases with Prostate Tumor Grade," Clinical Cancer Research: An Official Journal of the American Association for Cancer Research, Dec. 2001, vol. 7, no. 12, December 2001, pgs. 3857-3861
/S.W./		Bidgood, Matthew J. et al., "Type IIA Secretory Phospholipase A <sub>2</sub> Up-Regulates Cyclooxygenase-2 and Amplifies Cytokine-Mediated Prostaglandin Production in Human Rheumatoid Synoviocytes" Journal of Immunology, September 1, 2000, vol. 165, no. 5, pgs. 2790-2797
/S.W./		Menschikowski, M. et al. "Expression of Secretory Group IIA Phospholipase A <sub>2</sub> In Relation to the Presence of Microbial Agents, Macrophage Infiltrates, and Transcripts of Proinflammatory Cytokines in Human Aortic Tissues," Arterioscler Thromb Vasc Biol, pgs. 751-762 June 16, 1999

Examiner Signature

/Sharon Wen/

Date Considered

10/23/2007

<sup>1</sup>Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



Sheet 1 of 1

FORM PTO 1449 (modified)

U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICE  
LIST OF REFERENCES CITED BY APPLICANT(S)  
(Use several sheets if necessary)

Attorney Docket - P71167US0

Application No. - 10/572,875

Applicant - Sheriff et al.

Filing Date - March 22, 2006

U.S. PATENT DOCUMENTS

Examiner <sup>†</sup>	Ref. #	Document No.		Date	Patentee/Applicant

FOREIGN PATENT DOCUMENTS

	Country	Document No.	Translation Abstract	Date	Patentee
			<input type="checkbox"/> <input type="checkbox"/>		
			<input type="checkbox"/> <input type="checkbox"/>		
			<input type="checkbox"/> <input type="checkbox"/>		
			<input type="checkbox"/> <input type="checkbox"/>		

NON-PATENT DOCUMENTS

Examiner <sup>†</sup>	Ref. #	Author (in CAPITAL LETTERS), Title, Book or Periodical, Volume, Date, Pages
/S.W./		Hundley, T.R. et al., "Characteristics of Arachidonic Acid Generation in Human Basophils: Relationship Between the Effects of Inhibitors of Secretory Phospholipase A <sub>2</sub> Activity and Leukotriene C <sub>4</sub> Release," The Journal of Pharmacology and Experimental Therapeutics, Mar 1998, Vol. 284, No. 3, pgs. 847-857
/S.W./		Thwin, Maung-Maung et al., "Functional site of endogenous phospholipase A <sub>2</sub> inhibitor from python serum," European Journal of Biochemistry/Feb. Jan 2002, vol. 269, 719-727
/S.W./		Furue, Shingo, MS. et al., "Therapeutic time-window of a group IIA phospholipase A <sub>2</sub> inhibitor in rabbit acute lung injury: Correlation with lung surfactant protection," Critical Care Medicine, April 2001, vol. 29, no. 4, pgs. 719-727
/S.W./		Niessen, Hans W.M. et al., "Type II secretory phospholipase A2 in cardiovascular disease: a mediator in atherosclerosis and ischemic damage to cardiomyocytes?" Cardiovascular Research, 15 Oct. 2003, vol. 60, no. 1, 4 September 2003, pgs. 68-77
/S.W./		Graff, Jeremy R. et al., "Expression of Group IIA Secretory Phospholipase A2 Increases with Prostate Tumor Grade," Clinical Cancer Research: An Official Journal of the American Association for Cancer Research, Dec. 2001, vol. 7, no. 12, December 2001, pgs. 3857-3861
/S.W./		Bidgood, Matthew J. et al., "Type IIA Secretory Phospholipase A <sub>2</sub> Up-Regulates Cyclooxygenase-2 and Amplifies Cytokine-Mediated Prostaglandin Production in Human Rheumatoid Synoviocytes" Journal of Immunology, September 1, 2000, vol. 165, no. 5, pgs. 2790-2797
/S.W./		Menschikowski, M. et al. "Expression of Secretory Group IIA Phospholipase A <sub>2</sub> in Relation to the Presence of Microbial Agents, Macrophage Infiltrates, and Transcripts of Proinflammatory Cytokines in Human Aortic Tissues," Arterioscler Thromb Vasc Biol, pgs. 751-762 June 16, 1999

Examiner Signature

/Sharon Wen/

Date Considered  
10/23/2007

<sup>†</sup>Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



Sheet 1 of 1

FORM PTO 1449 (modified)

**U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICE**  
**LIST OF REFERENCES CITED BY APPLICANT(S)**  
(Use several sheets if necessary)

Attorney Docket = P71167US0

**Application No.** - 10/572 875

**Applicant** – SHERIFF et al.

**Filing Date** - March 22, 2006

## U.S. PATENT DOCUMENTS

## FOREIGN PATENT DOCUMENTS

		Country	Document No.	Translation	Abstract	Date	Patentee
/S.W./		WO	98/53846	<input type="checkbox"/>	<input type="checkbox"/>	12-03-1998	PILON et al.
/S.W./		WO	98/55504	<input type="checkbox"/>	<input type="checkbox"/>	12-10-1998	MOUNIER et al.
/S.W./		WO	02/08189 A1	<input type="checkbox"/>	<input type="checkbox"/>	01-31-2002	REID et al.
/S.W./		WO	96/20959	<input type="checkbox"/>	<input type="checkbox"/>	07-11-1996	KAWAUCHI et al.
				<input type="checkbox"/>	<input type="checkbox"/>		
				<input type="checkbox"/>	<input type="checkbox"/>		

## **NON-PATENT DOCUMENTS**

**Examiner Signature**


/Sharon Wen/

### Date Considered

10/23/2007

<sup>1</sup>Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Sheet 1 of 1



FORM PTO 1449 (modified)

U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICELIST OF REFERENCES CITED BY APPLICANT(S)  
(Use several sheets if necessary)

Attorney Docket - P71167US0

Application No. - 10/572,875

Applicant - SHERIFF et al.

Filing Date - June 21, 2006

## U.S. PATENT DOCUMENTS

Examiner <sup>†</sup>	Ref. #	Document No.		Date	Patentee/Applicant

## FOREIGN PATENT DOCUMENTS

		Country	Document No.	Translation Abstract	Date	Patentee
				<input type="checkbox"/> <input type="checkbox"/>		
				<input type="checkbox"/> <input type="checkbox"/>		
				<input type="checkbox"/> <input type="checkbox"/>		

## NON-PATENT DOCUMENTS

Examiner <sup>†</sup>	Ref. #	Author (In CAPITAL LETTERS), Title, Book or Periodical, Volume, Date, Pages)
/S.W./		P. N. BERNATCHEZ et al., "VEGF stimulation of endothelial cell PAF synthesis is mediated by group V 14 kDa secretory phospholipase A <sub>2</sub> ," British Journal of Pharmacology (2001) 134, 197-205
/S.W./		M. McCORD et al., "Human Keratinocytes Possess an sn-2 Acylhydrolase that is Biochemically Similar to the U937-Derived 85-kDa Phospholipase A <sub>2</sub> ," The Journal of Investigative Dermatology, Vol. 102, No. 6, June 1994
/S.W./		J. M. STADEL et al., "Recombinant Human Secretory Phospholipase A <sub>2</sub> : Purification and Characterization of the Enzyme for Active Site Studies," Journal of Molecular Recognition, Vol. 5, 145-153 (1992)
/S.W./		E. ABRAHAM et al., "Efficacy and safety of LY315920Na/S-5920, a selective inhibitor of 14-kDa group IIA secretory phospholipase A <sub>2</sub> , in patients with suspected sepsis and organ failure," Crit Care Med 2003 Vol. 31, No. 3
/S.W./		L. TOUQUI et al., "Mammalian Secreted Phospholipases A <sub>2</sub> and Their Pathophysiological Significance in Inflammatory Diseases," Current Molecular Medicine 2001, 1, 739-754
/S.W./		GENBANK accession No. NM_000300 "Homo sapiens phospholipase A2, group IIA (platelets, synovial fluid) (PLA2G2A), mRNA"
/S.W./		BIDGOOD, J. M., "Type IIA Secretory Phospholipase A <sub>2</sub> Up-Regulates Cyclooxygenase-2 and Amplifies Cytokine-Mediated Prostaglandin Production in Human Rheumatoid Synoviocytes <sup>1</sup> ," The Journal of Immunology, vol. 165, pgs. 2790-2797

Examiner Signature

/Sharon Wen/

Date Considered  
10/23/2007

<sup>†</sup>Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.